Why the study?
Does compound 21 reduce proinflammatory cytokines in human and murine dermal fibroblasts and in vivo cutaneous inflammation models?
Population
Primary human and murine dermal fibroblasts and bleomycin-induced toxic cutaneous inflammation model
Comparison
Compound 21, an orally active, nonpeptide AT2… vs AT2 receptor antagonist PD123319, AT2…
Design
Preclinical
Authors
Loading...
Preclinical AT2 agonism with C21 attenuates IL-6 in models; hypothesis-generating for human inflammation, should not yet change practice.
Does compound 21 reduce proinflammatory cytokines in human and murine dermal fibroblasts and in vivo cutaneous inflammation models?
Direct AT2 receptor stimulation with the nonpeptide agonist C21 exerts anti-inflammatory effects by reducing IL-6 and inhibiting NF-kappaB in vitro and in vivo.
Rompe et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: